Compare Abeona Therapeutics Inc (ABEO) vs HCA Health Inc (HCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs HCA Health Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while HCA Health Inc trades at $411.55 (market cap $93.86B). The key difference: HCA Health Inc is far larger — about 251.4× Abeona Therapeutics Inc's market cap, and HCA Health Inc pays a 0.74% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HCA | |
|---|---|---|
Market Cap | $373.32M | $93.86B |
Sector | Health | Health |
52-Week High | $7.23 | $545.13 |
52-Week Low | $4.17 | $334.32 |
Enterprise Value | $228.22M | $142.77B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
HCA Healthcare trades at $423.11, up 3.07% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with revenue growth to $75.6B in 2025 and consistent earnings beats. Recent news highlights capacity expansion and gene therapy advancements. Technical indicators suggest bullish trends, though RSI signals potential overbought conditions near-term.
Outlook remains positive given earnings momentum and strategic investments, but risks include high debt levels and healthcare regulatory pressures. Analyst consensus targets $493 with 65% buy ratings, indicating upside potential from current levels amid manageable execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
